StreetInsider.com News Articles

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

Fri, 29 May 2026 08:05:00 -0400

--ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations--

--NeuroPace to engage neurosurgeon community through clinical education, product feedback sessions, and hands-on booth demonstrations--

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

Fri, 29 May 2026 08:05:00 -0400

--ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations--

--NeuroPace to engage neurosurgeon community through clinical education, product feedback sessions, and hands-on booth demonstrations--

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

Fri, 29 May 2026 08:05:00 -0400

--ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations--

--NeuroPace to engage neurosurgeon community through clinical education, product feedback sessions, and hands-on booth demonstrations--

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

Fri, 29 May 2026 08:05:00 -0400

--ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations--

--NeuroPace to engage neurosurgeon community through clinical education, product feedback sessions, and hands-on booth demonstrations--

NeuroPace receives FDA approval for AI-driven epilepsy care tool

Fri, 29 May 2026 08:00:31 -0400

NeuroPace Inc. (NASDAQ: NPCE) announced FDA approval of ECoG Assistant, an artificial intelligence tool designed to support clinicians treating epilepsy patients. The Mountain View, California-based medical device company developed the tool using its database of intracranial EEG data.

ECoG Assistant analyzes brain data captured through NeuroPace's RNS System to help physicians review electroencephalography records more efficiently. The AI model was trained on 124,450 epileptologist-labeled intracranial EEG long-episode records to identify patterns of clinical interest.

The tool provides physicians with a trends report showing ECoGs of Interest over multiple months and includes a Circadian Pattern Chart to examine timing patterns. According to the

NeuroPace receives FDA approval for AI-driven epilepsy care tool

Fri, 29 May 2026 08:00:31 -0400

The tool provides physicians with a trends report showing ECoGs of Interest over multiple months and includes a Circadian Pattern Chart to examine timing patterns. According to the

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

Fri, 29 May 2026 08:00:00 -0400

-- First in a suite of planned NeuroPace AI tools designed to deliver deeper data insights, support clinical outcomes and further enhance efficiency of RNS therapy --

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace’s broader AI platform strategy, leveraging the world’s only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed.

ECoG Assistant: Treatment Insights Simplified

ECoG Assistant is the first

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

Fri, 29 May 2026 08:00:00 -0400

-- First in a suite of planned NeuroPace AI tools designed to deliver deeper data insights, support clinical outcomes and further enhance efficiency of RNS therapy --

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace’s broader AI platform strategy, leveraging the world’s only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed.

ECoG Assistant: Treatment Insights Simplified

ECoG Assistant is the first

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

Fri, 29 May 2026 08:00:00 -0400

-- First in a suite of planned NeuroPace AI tools designed to deliver deeper data insights, support clinical outcomes and further enhance efficiency of RNS therapy --

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace’s broader AI platform strategy, leveraging the world’s only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed.

ECoG Assistant: Treatment Insights Simplified

ECoG Assistant is the first

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

Fri, 29 May 2026 08:00:00 -0400

-- First in a suite of planned NeuroPace AI tools designed to deliver deeper data insights, support clinical outcomes and further enhance efficiency of RNS therapy --

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace’s broader AI platform strategy, leveraging the world’s only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed.

ECoG Assistant: Treatment Insights Simplified

ECoG Assistant is the first

Form 4 NeuroPace Inc For: May 27 Filed by: Becker Joel

Thu, 28 May 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260528/26568338.html

Form 4 NeuroPace Inc For: May 27 Filed by: Becker Joel

Thu, 28 May 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260528/26568338.html

Form 4 NeuroPace Inc For: May 27 Filed by: Morrell Martha

Thu, 28 May 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260528/26568280.html

Form 4 NeuroPace Inc For: May 27 Filed by: Morrell Martha

Thu, 28 May 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260528/26568280.html

Form 4 NeuroPace Inc For: May 15 Filed by: Williams Patrick F.

Tue, 19 May 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260519/26522192.html

Form 4 NeuroPace Inc For: May 15 Filed by: Williams Patrick F.

Tue, 19 May 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260519/26522192.html

Form 4 NeuroPace Inc For: May 15 Filed by: Morrell Martha

Tue, 19 May 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260519/26521615.html

Form 4 NeuroPace Inc For: May 15 Filed by: Morrell Martha

Tue, 19 May 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260519/26521615.html

Form 4 NeuroPace Inc For: May 15 Filed by: Becker Joel

Tue, 19 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260519/26521605.html

Form 4 NeuroPace Inc For: May 15 Filed by: Becker Joel

Tue, 19 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260519/26521605.html

NeuroPace Inc (NPCE) PT Raised to $20 at H.C. Wainwright

Mon, 18 May 2026 07:07:29 -0400

(Updated - May 18, 2026 7:07 AM EDT)

H.C. Wainwright analyst Yi Chen raised the price target on NeuroPace Inc (NASDAQ: NPCE) to $20.00 (from $19.00) while maintaining a Buy rating.

The analyst commented: "Top- and bottom-line beat in 1Q26; FY2026 revenue guidance raised to $99-101M. Earlier this week, NeuroPace reported its 1Q26 financial results. Total revenue was $22.1M, representing 20.1% YoY growth (excluding DIXI Medical) and beating our projection of $21.5M. Of note, RNS system revenue was $21.7M, up 18.5% YoY. Net loss was $6.7M, or ($0.20) per share, less than our estimated loss of $7.2M. According to management, the company

NeuroPace Inc (NPCE) PT Raised to $20 at H.C. Wainwright

Mon, 18 May 2026 07:07:29 -0400

(Updated - May 18, 2026 7:07 AM EDT)

H.C. Wainwright analyst Yi Chen raised the price target on NeuroPace Inc (NASDAQ: NPCE) to $20.00 (from $19.00) while maintaining a Buy rating.

Form SCHEDULE 13G NeuroPace Inc Filed by: First Light Asset Management, LLC

Fri, 15 May 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260515/26507177.html

Form SCHEDULE 13G NeuroPace Inc Filed by: First Light Asset Management, LLC

Fri, 15 May 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260515/26507177.html

Form SCHEDULE 13G/A NeuroPace Inc Filed by: ORBIMED ADVISORS LLC

Fri, 15 May 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260515/26506915.html